University of Cincinnati (UC) researchers have discovered a biomarker, known as phosphatidylserine (PS), for pancreatic cancer that could be effectively targeted, creating a potential therapy for a condition that has a small survival rate. These findings, being published in the Oct. 4, 2013, online edition of PLOS ONE, also show that the use of a biotherapy consisting of a lysosomal protein, known as saposin C (SapC), and a phospholipid, known as dioleoylphosphatidylserine (DOPS), can be combined into tiny cavities, or nanovesicles, to target and kill pancreatic cancer cells.
Hey, check out all the research scientist jobs. Post your resume today!
